RT Journal Article
SR Electronic
T1 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 4 UK centres
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P228
VO 40
IS Suppl 56
A1 Mark Britton
A1 Timothy Howes
A1 Dinesh Saralaya
A1 Matthew Masoli
A1 Monica Nordstrom
A1 Karen Regan
A1 Deborah Hepburn
A1 Kate Welham
A1 Ismail Kasujee
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P228.abstract
AB Omalizumab is an effective adjunctive therapy for patients (age ≥6 years; European Union), with uncontrolled severe persistent allergic asthma. To evaluate the effectiveness of omalizumab on real-life outcomes in UK clinical settings, we retrospectively reviewed records from severe allergic asthma patients who were receiving omalizumab (150–600 mg q4wk or q2wk) at 4 UK centres. Data were compared for 12 months (Plymouth) or 2 years (Chertsey; Bradford; Colchester) pre-omalizumab and for the most recent assessment following omalizumab initiation.Patients (n=80; age 14–74 years) received omalizumab for an average of 1190 days (range: 112–4217). 82% patients responded to treatment at 16 weeks. There was a decrease in hospital admissions/bed days, ICU admissions, and accident & emergency (A&E) and GP visits (Table) and in oral corticosteroid (OCS) use post omalizumab initiation; mean maintenance dose of OCS pre- and post-omalizumab was 14.6 and 4.7 mg/day, respectively. Mean [SD] improvements were also observed in Asthma Quality of Life Questionnaire (AQLQ) score (+1.6[1.4]) and Asthma Control Test (+3.8[9.0]). Patients not receiving OCS at baseline (n=22) achieved higher mean [SD] AQLQ scores compared with those receiving OCS at baseline (n=49): 1.8[1.5] vs 1.6[1.3], respectively. These results demonstrate the effectiveness of omalizumab in a clinical setting, and further support the efficacy of omalizumab shown in clinical trials.View this table: